Overview of Diabetic Retinopathy (DR)

Resource	Address
Centers for Disease Control and Prevention (CDC). Prevalence of Diagnosed Diabetes. Updated December 29, 2021.	https://www.cdc.gov/diabetes/data/statistics- report/diagnosed-diabetes.html
Grading diabetic retinopathy from stereoscopic color fundus photographsan extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. <i>Ophthalmology</i> . 1991;98(5 suppl):786-806.	https://www.aaojournal.org/article/S0161- 6420(13)38012-9/pdf
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern [®] . <i>Ophthalmology</i> . 2020;127(1):P66-P145.	https://www.aaojournal.org/article/S0161- 6420(19)32092-5/fulltext
Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. <i>Diabetes Care.</i> 2004;27(suppl 1):S84-S87.	https://diabetesjournals.org/care/article/27/sup pl_1/s84/24669/Retinopathy-in-Diabetes
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. <i>Arch Ophthalmol.</i> 1984;102(4):520-526.	https://jamanetwork.com/journals/jamaophthal mology/article-abstract/635006
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. <i>Eye Vis (Lond)</i> . 2015;2:17.	https://eandv.biomedcentral.com/articles/10.11 86/s40662-015-0026-2
Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. <i>BMJ Open.</i> 2014;4(2):e004015.	https://bmjopen.bmj.com/content/4/2/e004015
National Eye Institute (NEI). Learn the facts about diabetic retinopathy. 2014.	https://www.nei.nih.gov/sites/default/files/neh ep-pdfs/NEI_DR_Infographic.pdf

Early vs Late-Stage Treatment in DR

Resource	Address
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern [®] . <i>Ophthalmology.</i> 2020;127(1):P66-P145.	https://www.aaojournal.org/article/S0161- 6420(19)32092-5/fulltext
Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. <i>World J Diabetes</i> . 2016;7(16):333-341.	https://www.wjgnet.com/1948- 9358/full/v7/i16/333.htm
Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. <i>Ophthalmology.</i> 2018;125(10):1608-1622.	https://www.aaojournal.org/article/S0161- 6420(17)33523-6/fulltext

Wykoff CC. Management of diabetes-related retinopathy. In: <i>Prevention and management of</i> <i>diabetes-related eye disease</i> . American Diabetes Association; May 2019.	https://www.ncbi.nlm.nih.gov/books/NBK54452 0/
Yokenawa Y, Modi YS, Kim LA, Skondra D, Kim JE, Wykoff CC. American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema. <i>J Vitreoretin Dis</i> . 2020;4(2):125-135.	https://journals.sagepub.com/doi/10.1177/2474 126419893829

The Role of Vascular Endothelial Growth Factor (VEGF) in DR

Resource	Address
Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. <i>N Engl J Med</i> . 1994;331(22):1480-1487.	https://www.nejm.org/doi/10.1056/NEJM19941 2013312203
Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. <i>Mayo Clin Proc.</i> 2012;87(1):77-88.	https://www.mayoclinicproceedings.org/article/ S0025-6196(11)00007-3/fulltext

Earlier Treatment to Prevent DR Progression

Resource	Address
Anti-VEGF Treatment for Prevention of PDR/DME. ClinicalTrials.gov identifier: NCT02634333. Updated November 24, 2021.	https://clinicaltrials.gov/ct2/show/NCT02634333
Arcadu F, Benmansour F, Maunz A, Willis J, Haskova Z, Prunotto M. Deep learning algorithm predicts diabetic retinopathy progression in individual patients. <i>NPJ Digit</i> <i>Med.</i> 2019;2:92.	https://www.nature.com/articles/s41746-019- 0172-3
Beam AL, Kohane IS. Translating artificial intelligence into clinical care. <i>JAMA</i> . 2016;316(22):2368-2369.	https://jamanetwork.com/journals/jama/article- abstract/2588761
Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. <i>Ophthalmology</i> . 2013;120(10):2013-2022.	https://www.aaojournal.org/article/S0161- 6420(13)00212-1/fulltext
Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. <i>Arch Ophthalmol.</i> 2012;130(9):1153-1161.	https://jamanetwork.com/journals/jamaophthal mology/fullarticle/1149410

Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. <i>Ophthalmology</i> . 2014;121(9):1783-1789.	https://www.aaojournal.org/article/S0161- 6420(14)00245-0/fulltext
Goldberg RA, Hill L, Abolian A, Stoilov I. What happens to diabetic retinopathy severity scores with less aggressive treatment? A post hoc analysis of the RISE/RIDE open- label extension study examining instability of DRSS with intermittent VEGF suppression. Presented at: Retina Society Annual Meeting; September 21-22, 2020; Virtual.	https://www.retinasociety.org/content/meeting archive/2020/goldberg-roger-what-happens-to- diabetic-retinopathy.pdf
Maturi RK, Glassman AR, Josic K, et al. Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The Protocol W randomized clinical trial. <i>JAMA Ophthalmol</i> . 2021;139(7):701-712.	https://jamanetwork.com/journals/jamaophthal mology/fullarticle/2778074
Mazhar K, Varma R, Choudhury F, et al. Severity of diabetic retinopathy and health-related quality of life: The Los Angeles Latino Eye Study. <i>Ophthalmology</i> . 2011;118(4):649-655.	https://www.aaojournal.org/article/S0161- 6420(10)00819-5/fulltext
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA). ClinicalTrials.gov identifier: NCT02718326. Updated July 30, 2020.	https://clinicaltrials.gov/ct2/show/NCT02718326
Willis JR, Doan QV, Gleeson M, et al. Vision-related functional burden of diabetic retinopathy across severity levels in the United States. <i>JAMA Ophthalmol</i> . 2017;135(9):926-932.	https://jamanetwork.com/journals/jamaophthal mology/fullarticle/2643965
Wykoff CC, Khurana RN, Nguyen QD, et al. Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy. <i>Diabetes Care</i> . 2021;44(3):748-756.	https://diabetesjournals.org/care/article/44/3/7 48/138555/Risk-of-Blindness-Among-Patients- With-Diabetes-and
Wykoff CC, Marcus DM, Midena E, et al. Intravitreal aflibercept injection in eyes with substantial vision loss after laser photocoagulation for diabetic macular edema: Subanalysis of the VISTA and VIVID randomized clinical trials. <i>JAMA Ophthalmol.</i> 2017;135(2):107-114.	https://jamanetwork.com/journals/jamaophthal mology/fullarticle/2594015
Wykoff CC, Shah C, Dhoot D, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. <i>Ophthalmology</i> . 2019;126(8):1171-1180.	https://www.aaojournal.org/article/S0161- 6420(18)33320-7/fulltext

Optimizing Anti-VEGF Dosing Regimens in DR

Resource	Address
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION). ClinicalTrials.gov identifier: NCT04503551. Updated May 16, 2022.	https://clinicaltrials.gov/ct2/show/NCT04503551
Freund KB, Korobelnik JF, Devenyi R, et al. Treat-and- extend regimens with anti-VEGF agents in retinal diseases: A literature review and consensus recommendations. <i>Retina</i> . 2015;35(8):1489-1506.	https://journals.lww.com/retinajournal/Abstract /2015/08000/TREAT_AND_EXTEND_REGIMENS_ WITH_ANTI_VEGF_AGENTS_IN.1.aspx
Hendrick AM, Ip MS. Managing diabetic eye disease with intravitreal anti-VEGF injections. <i>Retina Today. March</i> 2016:74-77.	https://retinatoday.com/articles/2016- mar/managing-diabetic-eye-disease-with- intravitreal-anti-vegf-injections
Maturi RK, Glassman AR, Josic K, et al. Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The Protocol W randomized clinical trial. <i>JAMA Ophthalmol</i> . 2021;139(7):701-712.	https://jamanetwork.com/journals/jamaophthal mology/fullarticle/2778074
Patel P, Shah CP. A peek into the diabetic retinopathy pipeline. <i>Rev Ophthalmol.</i> April 15, 2021.	https://www.reviewofophthalmology.com/articl e/a-peek-into-the-diabetic-retinopathy-pipeline
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHOTON). ClinicalTrials.gov identifier: NCT04429503. Updated June 7, 2022.	https://clinicaltrials.gov/ct2/show/NCT04429503
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda). ClinicalTrials.gov identifier: NCT04108156. Updated July 12, 2022.	https://clinicaltrials.gov/ct2/show/NCT04108156
Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: A review of the latest treatment options. <i>Cells.</i> 2021;10(5):1049.	https://www.mdpi.com/2073-4409/10/5/1049
Weng C. The expanding role of anti-VEGF in the management of diabetic retinopathy. <i>Retinal Physician</i> . September 1, 2020.	https://www.retinalphysician.com/issues/2020/s eptember-2020/the-expanding-role-of-anti-vegf- in-the-management

Trials Targeting High-Risk Nonproliferative DR (NPDR)

Resource	Address
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION). ClinicalTrials.gov identifier: NCT04503551. Updated May 16, 2022.	https://clinicaltrials.gov/ct2/show/NCT04503551
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW). ClinicalTrials.gov identifier: NCT05066230. Updated July 5, 2022.	https://clinicaltrials.gov/ct2/show/NCT05066230
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy (CANBERRA). ClinicalTrials.gov identifier: NCT04265261. Updated July 26, 2022.	https://clinicaltrials.gov/ct2/show/NCT04265261
ADVM-022 Intravitreal Gene Therapy for DME (INFINITY). ClinicalTrials.gov identifier: NCT04418427. Updated January 11, 2022.	https://clinicaltrials.gov/ct2/show/NCT04418427
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE). ClinicalTrials.gov identifier: NCT04567550. Updated July 15, 2022.	https://clinicaltrials.gov/ct2/show/NCT04567550